Análise imunoistoquímica da expressão dos marcadores ALCAM e ALDH1 em pacientes com adenocarcinoma colorretal e associação com desfechos clinicopatológicos
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: O câncer colorretal apresenta alta mortalidade global, requerendo que investigações sejam realizadas para melhor compreender esta enfermidade. Marcadores tumorais têm surgido como sinalizadores de diagnóstico, manejo e prognóstico das neoplasias. Novos marcadores são estudados neste cenário.
Objetivo: Verificar se há correlação da expressão por imunoistoquímica das proteínas ALCAM e ALDH1 em tecido com adenocarcinoma colorretal com as características epidemiológicas, clinicopatológicas, seu impacto na progressão de doença, e no óbito.
Método: Revisão narrativa com base em publicações selecionas a partir de pesquisa em plataformas virtuais. Inicialmente foi realizada busca por descritores DeCS relativos ao tema, sendo escolhidos: “câncer colorretal, ALCAM e ALDH1” com busca AND ou OR, primeiramente pelo título e resumo e, depois, por leitura na íntegra dos selecionados.
Resultado: Foram incluídos 52 artigos.
Conclusão: A expressão por imunoistoquímica dos marcadores ALCAM e ALDH1 não apresentou associação com a progressão de doença e ao evento óbito, também não foi possível observar relação de correspondência com os marcadores avaliados
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
GLOBOCAN. Cancer Today Globocan. Disponível em: www.cgo.iarc.fr. Acesso em 15 de agosto de 2020.
Weichert W, Beier D, Russo L, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004;57(11):1160-4. Doi: 10.1136/jcp.2004.016238
Siegel RL, Miller KD, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177-93. Doi: 10.3322/caac.21395
Tomita H, Tanaka T, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7(10). Doi: 10.18632/oncotarget.6920
Cardella J, Spithoff K, Braz S, Maier BA, Greco E, Last L, et al. Compliance, attitudes and barriers to post-operative colorectal cancer follow-up. J Eval Clin Pract. 2008;14(3):407-15. Doi: 10.1111/j.1365-2753.2007.00880.x
Parsons SF, Lee G, Spring FA, Houlihan JM, Simpson KL, Mawby WJ, et al. The Lutheran blood group glycoprotein, another member of the immunoglobulin superfamily, is widely expressed in human tissues and is developmentally regulated in human liver. Proc Natl Acad Sci U S A. 1995;92(12):5496-500. Doi: 10.1073/pnas.92.12.5496
Zhang WW, Li L, Li D, Sun X, Erkan M, Kleeff J, et al. Activated leukocyte cell adhesion molecule regulates the interaction between pancreatic cancer cells and stellate cells. Mol Med Rep. 2016;14(4):3627-33. Doi: 10.3892/mmr.2016.5681
Hansen A, Swart G, Zijlstra A. ALCAM. AfCS-Nature Molecule Pages. 2011;2011. Doi:10.1038/mp.a004126.01
Swart G. Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002;81(6):313-21. Doi: 10.1078/0171-9335-00256
Van Kempen LC, Nelissen JM, Degen WG, Torensma R, Weidle UH, Bloemers HP, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001;276(28):25783-90. Doi: 10.1074/jbc.M011272200
Lauwaet T, Oliveira MJ, Callewaert B, Leroy A. Molecular mechanisms of invasion by cancer cells, leukocytes and microorganisms. Microbes Infect. 2000;2(8):923-31. Doi: 10.1016/s1286-4579(00)00394-4
Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008;151(3):122-8. Doi: 10.1016/j.trsl.2007.09.006
Sawhney M, Rohatgi N, Kaur J, Kaur J, DattaGupta S, Shukla NK, et al. Cytoplasmic accumulation of activated leukocyte cell adhesion molecule is a predictor of disease progression and reduced survival in oral cancer patients. Int J Cancer. 2009;124(9):2098-105. Doi: 10.1002/ijc.24192
Mezzanzanica D, Balladore E, Turatti F, Staurengo S, Losa M, Balladore E, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 2008;14(6):1726-33. Doi: 10.1158/1078-0432.CCR-07-0428
Kahlert C, Pecqueux M, Halama N, Bergmann F, Schirmacher P, Kenngott HG, et al. Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer. 2009;101(3):457-64. Doi: 10.1038/sj.bjc.6605136
Tomita K, van Bokhoven A, van Leenders GJ, Kiemeney LA, Karthaus HFM, Vriesema J, et al. Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer Patients. UroOncology. 2003;3(3-4):121-9. Doi 10.1080/15610950310001632322
King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG, et al. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res. 2004;6(5):R478-87. Doi: 10.1186/bcr815
Tachezy M, Zander H, Wolters-Eisfeld G, Marx A, Kaifi JT, Izbicki JR, et al. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients. J Surg Res. 2012;177(1):e15-20. Doi: 10.1016/j.jss.2012.02.013
Tomita K, van Bokhoven A, Jansen CF, Bussemakers MJ, Schalken JÁ, et al. Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. Biochem Biophys Res Commun. 2000;267(3):870-4. Doi: 10.1006/bbrc.1999.2040
Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer. 2010;103(3):382-90. Doi: 10.1038/sj.bjc.6605762
Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer. Cancer Invest. 2009;27(8):844-50. Doi: 10.1080/07357900902744502
Zhang Y, Wang Z, Yu J, Ren J, Guan Y. Meta-analysis indicating that high ALCAM expression predicts poor prognosis in colorectal cancer. Oncotarget. 2017;8(29):48272-81.Doi: 10.18632/oncotarget.17707
Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006;59(4):403-9. Doi: 10.1136/jcp.2005.028209
McCabe KE, Wu AM, Tomlinson JS, Wu W, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012;14(3):336-47. Doi: 10.1007/s11307-011-0500-8
Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y. A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother. 2010;59(11):1665-74. Doi: 10.1007/s00262-010-0892-3
Jackson B, Black W, Janowska E, Black W, Vasiliou K, Nebert DW, et al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics. 2011;5(4):283-303. Doi: 10.1186/1479-7364-5-4-283
Sobreira TJP, Marlétaz F, Simões-Costa M, Schechtman D, Pereira AC, Brunet F, et al. Structural shifts of aldehyde dehydrogenase enzymes were instrumental for the early evolution of retinoid-dependent axial patterning in metazoans. Proc Natl Acad Sci U S A. 2011;108(1):226-31.Doi: 10.1073/pnas.101122310
Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol. 2008;4(6):697-720. Doi: 10.1517/17425255.4.6.697
Lindahl R. Aldehyde Dehydrogenases and Their Role in Carcinogenesis. Crit Rev Biochem Mol Biol. 1992;27(4-5):283-335. Doi: 10.3109/10409239209082565
Vasiliou V, Nebert DW. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum Genomics. 2005;2(2):138-43. Doi: 10.1186/1479-7364-2-2-138
Nebert DW, Wain HM. Update on human genome completion and annotations: gene nomenclature. Hum Genomics. 2003;1(1):66-71. Doi: 10.1186/1479-7364-1-1-66
Chen Y, Orlicky DJ, Matsumoto A, Singh S, Thompson DC, Vasiliou V. Aldehyde dehydrogenase 1B1 (ALDH1B1) is a potential biomarker for human colon cancer. Biochem Biophys Res Commun. 2011;405(2):173-9. Doi: 10.1016/j.bbrc.2011.01.002
Baccelli I, Trumpp A. The evolving concept of cancer and metastasis stem cells. J Cell Biol. 2012;198(3):281-93. Doi: 10.1083/jcb.201202014
Boman BM, Huang E. Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol. 2008;26(17):2828-38. Doi: 10.1200/JCO.2008.17.6941
O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10. Doi:10.1038/nature05372
Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde J, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111-20. Doi: 10.1172/JCI34401
Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, et al. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells. 2004;22(7):1142-51. Doi: 10.1634/stemcells.2004-0170
Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555-67. Doi: 10.1016/j.stem.2007.08.014
Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. Cancer Res. 2009;69(8):3382-9. Doi: 10.1158/0008-5472.CAN-08-4418
Sanders MA, Majumdar APN. Colon cancer stem cells: implications in carcinogenesis. Front Biosci (Landmark Ed). 2011;16:1651-62. Doi: 10.2741/3811
Carpentino JE, Hynes MJ, Appelman HD, Zheng T, Steindler DA, Scott EW, et al. Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res. 2009;69(20):8208-15. Doi: 10.1158/0008-5472.CAN-09-1132
Vassalli G. Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells. Stem Cells Int. 2019;2019:3904645. Doi: 10.1155/2019/3904645
Fitzgerald TL, McCubrey JA, Biswas T, Starr S, Sigounas G. The impact of Aldehyde dehydrogenase 1 expression on prognosis for metastatic colon cancer. J Surg Res. 2014;192(1):82-9. Doi: 10.1016/j.jss.2014.05.054
Hou Y, Liu YY, Zhao XK. Expression of aldehyde dehydrogenase 1 in colon cancer. Asian Pac J Trop Med. 2013;6(7):574-7. Doi: 10.1016/S1995-7645(13)60099-1
Holah NS, Aiad HA, Asaad NY, Elkhouly EA, Lasheen AG. Evaluation of the Role of ALDH1 as Cancer Stem Cell Marker in Colorectal Carcinoma: An Immunohistochemical Study. J Clin Diagn Res. 2017;11(1):EC17-EC23. Doi: 10.7860/JCDR/2017/22671.9291
Hessman CJ, Bubbers EJ, Billingsley KG, Herzig DO, Wong MH. Loss of expression of the cancer stem cell marker aldehyde dehydrogenase 1 correlates with advanced-stage colorectal cancer. Am J Surg. 2012;203(5):649-53. Doi: 10.1016/j.amjsurg.2012.01.003
Zhou F, Mu YD, Liang J, Liu ZX, Chen HS, Zhang JF. Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol Lett. 2014;7(2):507-12. Doi: 10.3892/ol.2013.1723
Chen J, Li Y, Yu TS, Chang W, Yuan W, Ma Z, et al. Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2015;10(12):e0145164. Doi: 10.1371/journal.pone.0145164
Kozovska Z, Gabrisova V, Kucerova L, Durinikova E, Demkova L, Jargasova S, et al. ALDH1A inhibition sensitizes colon cancer cells to chemotherapy. BMC Cancer. 2018;18(1):656. Doi: 10.1186/s12885-018-4572-6
Koppaka V, Thompson DC, Chen Y, Ellermann M, Nicolaou KC, Juvonen RO, et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol Rev. 2012;64(3):520-39. Doi: 10.1124/pr.111.005538
Chang PM-H, Chen PM, Hsiao M, Lu HJ, Liu T, Chen MH, et al. Transcriptome analysis and prognosis of ALDH isoforms in human cancer. Sci Rep. 2018;8(1):2713. Doi: 10.1038/s41598-018-21123-4
Modarai SR, Gupta A, Opdenaker LM, Kowash R, Masters G, Viswanathan V, et al. The anti-cancer effect of retinoic acid signaling in CRC occurs via decreased growth of ALDH+ colon cancer stem cells and increased differentiation of stem cells. Oncotarget. 2018;9(78):34658-69. Doi: 10.18632/oncotarget.26157
Monteiro JM, Isolan GR, Barbosa B, Brito JNP de O, de Araujo RL, Almeida T. É possível prever a mortalidade molecular em meduloblastomas pela análise dos receptores de membrana CD114?. BioSCIENCE. 2023;81(2):88-96. Doi: 10.55684/81.2.17
Coelho JCU, de Freitas ACT, da Cunha FB, Kishi NM. Neoplasia cística mucinosa do pâncreas. BioSCIENCE. 2023;81(2):97-100. Doi: 10.55684/81.2.18